RESTON, Va., Feb. 8, 2017 /PRNewswire/ -- Leidos (NYSE: LDOS), a global science and technology company, was awarded a contract by the Defense Threat Reduction Agency (DTRA) to support DTRA's Cooperative Biological Engagement Program (CBEP) and Cooperative Threat Reduction (CTR) Program through a worldwide Scientific & Technical Engagement Partnership (STEP) program. The single-award, time and materials contract has a one-year base period of performance, four one-year options, and a total contract value of approximately $170 million if all options are exercised. Work will be performed primarily in Northern Virginia and internationally in several combatant command areas of responsibility.
DTRA provides the Department of Defense's core intellectual, technical, and operational support expertise for countering threats posed by weapons of mass destruction and high-yield explosives. The CTR Program promotes collaboration with international and non-governmental partners to advance regional engagement and multilateral cooperation in the biological warfare non-proliferation sector. The STEP Program will build long-term partnerships between strong research and technical centers and CBEP partner-country institutions to reduce biological threats through enhanced biological safety and security, awareness of biological risks, and knowledge related to biological pathogen research in foreign countries.
Under this new contract, Leidos will partner with industry, research institutions, non-governmental organizations, and local scientists to develop collaborative overseas research programs, and provide specialized training in laboratory research and containment facilities engineering, public health preparedness and emergency response, and disease outbreak field surveillance and response.
"Leidos is proud of the decades of support we have provided to DTRA's critical mission and we are honored to have been selected to support DTRA's key international partner engagement," said Leidos Defense and Intelligence President, Tim Reardon. "The international assistance provided under this contract will strengthen US Government international outreach in countering threats posed by weapons of mass destruction, particularly biological weapons. This outreach, research, and training will help the US and our international partners prevent or mitigate CBRNE events throughout the world."
Leidos is a global science and technology solutions leader working to solve the world's toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company's 33,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported pro forma annual revenues of approximately $10 billion for the fiscal year ended Jan. 1, 2016 after giving effect to the recently completed combination of Leidos with Lockheed Martin's Information Systems & Global Solutions business (IS&GS). For more information, visit www.Leidos.com.
Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in the company's Annual Report on Form 10-K for the period ended January 1, 2016, and other such filings that Leidos makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.
Melissa Koskovich, SVP Communications, (571) 526-6850,
Jason Kello, Director - Media Relations,
More Content by Media Relations